OR WAIT null SECS
April 01, 2025
Video
Daniel Judge, MD, discusses data from a prespecified analysis of ATTRibute-CM examining the effects of acoramidis with and without concomitant tafamidis use.
Ahmad Masri, MD, MS, discusses data detailing the effects of aficamten in oHCM from the FOREST-HCM OLE study at ACC.25.
March 31, 2025
Jose Lopez, MD, discusses findings and perspective into racial and ethnic differences in DbCM from the ARISE-HF trial.
March 28, 2025
In this video, the last in a 4-part series, panelists discuss how ongoing research and efforts could shape the future of ATTR-CM management.
In this video, part 3 of a 4-part series, panelists discuss the impact of recent approvals and pipeline developments on the outlook for ATTR-CM management.
In this video, part 2 of a 4-part series, panelists discuss on recent advancements in imaging and biomarker-based diagnostics for ATTR-CM
In this video, part 1 of a 4-part series, panelists discuss recent advancements in ATTR-CM management.
March 22, 2025
Article
Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.
March 21, 2025
The approval expands the indication for vutrisiran, which becomes the first therapeutic approved by the FDA for the treatment of ATTR-CM.
March 11, 2025
The regulatory agency granted 510(k) clearance to Caristo Diagnostics' image analysis software to aid in coronary artery disease diagnosis.
